CompletedNCT06359899
Safety study of AK0901 in ADHD
This study is completed in China. It is testing AK0901 for ADHD.
In BeijingADHDDrugA study involving a medication or substance.From 6 Years to 12 Years
Study directory
Back to overviewMental health studies with practical context.
Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.
CompletedNCT02969369
Safety study of SEP-363856 in Schizophrenia
This study is completed in the United States. It is testing SEP-363856 for Schizophrenia.
Multiple locations, including FresnoSchizophreniaDrugFrom 55 Years to 105 Years
CompletedNCT02417064
Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression
This study is completed in the United States, in France, in Canada, .... It is testing efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression.
Multiple locations, including BirminghamDepressionDrugFrom 18 Years to 64 Years
CompletedNCT02418585
Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression
This study is completed in the United States, in Czechia, in Germany, .... It is testing efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression.
Multiple locations, including BirminghamDepressionDrugFrom 18 Years to 64 Years
CompletedNCT02422186
Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression
This study is completed in the United States, in France, in the United Kingdom, .... It is testing efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant for treatment-resistant depression.
Multiple locations, including San DiegoDepressionDrugOver 65 Years
CompletedNCT06136936
Overall Effects of Treatment With Abbreviated CT-156 for schizophrenia
This study is completed in the United States. It is testing Overall Effects of Treatment With Abbreviated CT-156 for schizophrenia.
In New YorkSchizophreniaBehavioralOver 18 Years
CompletedNCT01206517
Safety study of sublingual Asenapine in schizophrenia
This study is completed. It is testing sublingual Asenapine for schizophrenia.
Location not clearly listedBipolarity, SchizophreniaDrugFrom 10 Years to 17 Years
CompletedNCT06024239
Safety study of Pharmacokinetics, Safety, and Tolerability of ABBV-932 in anxiety
This study is completed in the United States. It is testing Pharmacokinetics, Safety, and Tolerability of ABBV-932 for anxiety.
Multiple locations, including Los AlamitosBipolarity, AnxietyDrugFrom 18 Years to 65 Years
CompletedNCT05527964
Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab for Anxiety
This study is completed in Czechia. It is testing quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab for Anxiety.
In PragueAnxietyOtherOver 18 Years
TerminatedNCT05144685
Safety and Effectiveness of a Digital Therapeutic
This study was terminated in the United States. It focuses on Suicide prevention.
Multiple locations, including DenverSuicidalityBehavioralOver 18 Years
CompletedNCT00035802
Effectiveness of topiramate Compared to Placebo in Bipolarity
This study is completed. It is testing topiramate Compared to Placebo for Bipolarity.
Location not clearly listedBipolarity, SchizophreniaDrugFrom 13 Years to 17 Years
CompletedNCT03745820
Safety study of Safety and Efficacy of BIIB104 in schizophrenia
This study is completed in the United States, in the United Kingdom, in Germany, .... It is testing Safety and Efficacy of BIIB104 for schizophrenia.
Multiple locations, including BentonvilleSchizophreniaDrugFrom 18 Years to 55 Years
Public registry coverage is progressing
HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.